Publications by authors named "Nasana Vaidya"
Article Synopsis
- Transgenes in oncolytic viruses aim to enhance cancer immunotherapy, but their protein synthesis can be hindered by viral infections, reducing therapeutic effectiveness.
- Research on oncolytic herpes simplex virus-1 (HSV1) showed that using the US11 5' leader sequence improved protein translation compared to standard methods.
- The modified HSV1 with the US11 5' leader significantly enhanced antitumor immune response and survival rates in mouse models, highlighting the importance of optimizing transgene expression for better cancer treatment outcomes.
Residual cell-intrinsic innate immunity in cancer cells hampers infection with oncolytic viruses. Translational control of mRNA is an important feature of innate immunity, yet the identity of translationally regulated mRNAs functioning in host defense remains ill-defined. We report the translatomes of resistant murine "4T1" breast cancer cells infected with three of the most clinically advanced oncolytic viruses: herpes simplex virus 1, reovirus, and vaccinia virus.
View Article and Find Full Text PDF